This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (19)  • Contact me when this article is cited  Related Content  • Related letters  • Similar articles in this journal  Topic Collections  • Law and Medicine  • Cognitive Disorders  • Stroke  • Alert me on articles by topic  Social Bookmarking   What's this?

Kara Z. Bambauer, PhD; S. Claiborne Johnston, MD, PhD; Derek E. Bambauer, JD; Justin A. Zivin, MD, PhD

Arch Neurol. 2006;63:661-664.

Despite the US Food and Drug Administration's approval in 1996, tissue plasminogen activator (tPA) therapy for acute ischemic stroke remains substantially underused. We reviewed 3 potential reasons for low rates of tPA use: poor patient education, physicians' perceived risk of legal liability from negative patient outcomes, and insufficient reimbursement. The recent addition of diagnosis-related grouping code 559 will provide higher payment for stroke patients treated with tPA, creating a natural experiment to examine our third reason.

Author Affiliations: Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Mass (Dr K. Bambauer); Department of Neurology, University of California, San Francisco (Dr Johnston); Berkman Center for Internet & Society, Harvard Law School, Cambridge, Mass (Dr D. Bambauer); Department of Neurology, University of California San Diego, La Jolla (Dr Zivin).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Nonstroke Treatment
William M. Landau
Arch Neurol. 2006;63(10):1506.
EXTRACT | FULL TEXT  

Nonstroke Treatment—Reply
Kara Z. Bambauer, S. Claiborne Johnston, Derek E. Bambauer, and Justin A. Zivin
Arch Neurol. 2006;63(10):1506-1507.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact
Roussel et al.
Brain 2009;132:2219-2230.
ABSTRACT | FULL TEXT  

Review of current and emerging therapies in acute ischemic stroke
Novakovic et al.
Journal of NeuroInterventional Surgery 2009;1:13-26.
ABSTRACT | FULL TEXT  

Camera in the Emergency Department: The Evolution of Stroke Telemedicine
Meschia
Mayo Clin Proc. 2009;84:3-4.
FULL TEXT  

Atherosclerotic Peripheral Vascular Disease Symposium II: Stroke Intervention: State of the Art
Alberts et al.
Circulation 2008;118:2845-2851.
FULL TEXT  

Review of Tissue Plasminogen Activator, Ischemic Stroke, and Potential Legal Issues
Liang et al.
Arch Neurol 2008;65:1429-1433.
ABSTRACT | FULL TEXT  

Telemedicine for acute stroke: When virtual is as good as reality
Levine and McConnochie
Neurology 2007;69:819-820.
FULL TEXT  

New Approaches to Clinical Trials in Neuroprotection: Introduction
Goldberg
Stroke 2007;38:789-790.
FULL TEXT  

November 14 Highlight and Commentary: Eliminating delay in rt-PA administration
Neurology 2006;67:1533-1533.
FULL TEXT  

Nonstroke treatment.
Landau
Arch Neurol 2006;63:1506-1506.
FULL TEXT  

Stroke Thrombolysis: Slow Progress
Caplan
Circulation 2006;114:187-190.
FULL TEXT